Company
RANI +4.83%Rani Therapeutics Holdings, Inc.
Market Cap: $106.4 Million
USD as of Aug 2, 2026
$RANI +4.83% $RANI United States Healthcare Biotechnology US Healthcare US BiotechnologyRani Therapeutics Holdings, Inc. Market Capitalization Over Time
View HistoryEvolution of Rani Therapeutics Holdings, Inc. market cap in the past 5 years
Market capitalizations are calculated from the opening stock price at the beginning of each month.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $209.25 B |
| Vertex Pharmaceuticals | $121.09 B |
| Regeneron Pharmaceuticals | $78.52 B |
| argenx | $52.93 B |
| Beigene Ltd. | $51.33 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
| Lilly | $1.024 T |
| Johnson & Johnson | $617.78 B |
| AbbVie | $443.36 B |
| Roche | $418.93 B |
| UnitedHealth Group | $376.34 B |
Detailed Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Financials
| Last Financial Reports Date | None |
| Revenue TTM | $None |
| EBITDA | $None |
| Gross Profit TTM | $None |
| Profit Margin | % |
| Operating Margin | % |
| Quarterly Revenue Growth | % |
Stocks & Indexes
Rani Therapeutics Holdings, Inc. main stocks and indexes inclusions.
$RANINASDAQ Composite